Stock 002275 GUILIN SANJIN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Guilin Sanjin Pharmaceutical Co., Ltd.

Equities

002275

CNE100000DY9

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
14.3 CNY +0.92% Intraday chart for Guilin Sanjin Pharmaceutical Co., Ltd. -5.55% -1.31%
Apr. 26 Guilin Sanjin Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023 CI
Apr. 25 Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2022 2023 2024 2025
Capitalization 1 7,570 8,514 8,402 -
Enterprise Value (EV) 1 7,570 8,514 8,402 8,402
P/E ratio 23.2 x 20.1 x 14.5 x 12.3 x
Yield - 2.07% - -
Capitalization / Revenue - 3.92 x 3.15 x 2.71 x
EV / Revenue - 3.92 x 3.15 x 2.71 x
EV / EBITDA - 13.6 x 11.4 x 9.67 x
EV / FCF - - - -
FCF Yield - - - -
Price to Book - 3.02 x 2.59 x 2.37 x
Nbr of stocks (in thousands) 572,641 587,569 587,569 -
Reference price 2 13.22 14.49 14.30 14.30
Announcement Date 2/27/23 3/5/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025
Net sales 1 - 2,172 2,671 3,097
EBITDA 1 - 625 738.3 869.2
EBIT 1 - 518.3 686.1 818.1
Operating Margin - 23.87% 25.69% 26.41%
Earnings before Tax (EBT) 1 - 518.3 686.1 818.2
Net income 1 326 421.3 580 682
Net margin - 19.4% 21.71% 22.02%
EPS 2 0.5700 0.7200 0.9850 1.160
Free Cash Flow - - - -
FCF margin - - - -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share 2 - 0.3000 - -
Announcement Date 2/27/23 3/5/24 - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025
Net Debt - - - -
Net Cash position - - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - - - -
ROE (net income / shareholders' equity) - 14.7% 18.5% 20.9%
ROA (Net income/ Total Assets) - - 12% 12.1%
Assets 1 - - 4,833 5,636
Book Value Per Share 2 - 4.790 5.520 6.040
Cash Flow per Share 2 - 0.9300 1.020 1.060
Capex 1 - 22.7 31.2 34.5
Capex / Sales - 1.05% 1.17% 1.11%
Announcement Date 2/27/23 3/5/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Guilin Sanjin Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
14.3
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

1st Jan change Capi.
GUILIN SANJIN PHARMACEUTICAL CO., LTD. Stock Guilin Sanjin Pharmaceutical Co., Ltd.
-1.31% 1.16B
DONG-E-E-JIAO CO.,LTD. Stock Dong-E-E-Jiao Co.,Ltd.
+39.33% 6.11B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD. Stock Shijiazhuang Yiling Pharmaceutical Co., Ltd.
-18.38% 4.35B
TASLY PHARMACEUTICAL GROUP CO., LTD Stock Tasly Pharmaceutical Group Co., Ltd
-9.17% 3.18B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Stock Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
+3.98% 3.15B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. Stock Shandong Buchang Pharmaceuticals Co., Ltd.
-3.41% 2.51B
HENAN LINGRUI PHARMACEUTICAL CO., LTD. Stock Henan Lingrui Pharmaceutical Co., Ltd.
+48.74% 1.98B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD. Stock GuangYuYuan Chinese Herbal Medicine Co., Ltd.
-4.82% 1.74B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD. Stock Tibet Cheezheng Tibetan Medicine Co., Ltd.
-1.24% 1.63B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD Stock Tianjin Chase Sun Pharmaceutical Co.,Ltd
-8.96% 1.6B
Alternative Medicine
  1. Stock Market
  2. Equities
  3. 002275 Stock
  4. Financials Guilin Sanjin Pharmaceutical Co., Ltd.